Table 1. Patient and outcome characteristics of the study population.
| UP (n = 1068) |
EPE (n = 75) |
LPE (n = 177) |
GH (n = 139) |
SGA (n = 129) |
EH (n = 43) |
|
|---|---|---|---|---|---|---|
| Characteristics at inclusion | ||||||
| Maternal age (years) | 30.4±5.9 | 30.3±5.3 | 30.0±5.2 | 30.2±4.4 | 29.8±4.9 | 32.9±5.1* |
| Gestational age at assessment (weeks) | ||||||
| First trimester | 12.2±0.8 | 12.9±0.5* | 11.8±0.8* | 12.2±0.7 | 12.1±0.7 | 12.4±1.1 |
| Second trimester | 20.7±1.6 | 25.2±2.3* | 22.0±2.3* | 21.5±2.7* | 20.8±1.8 | 21.9±3.9* |
| Third trimester | 33.4±3.2 | 31.5±1.5* | 36.7±2.4* | 36.8±2.7* | 33.4±2.9 | 34.1±3.0 |
| Pre-pregnancy BMI (kg/m2) | 24.6±4.9 | 26.9±6.2* | 26.1±5.7* | 26.4±6.0* | 23.9±5.2 | 27.1±5.7* |
| Nulliparity (n,% women) | 502 (47) | 51 (68)* | 129 (73)* | 88 (63)* | 64 (50) | 21 (49) |
| Cigarette smoker (n,% women) | 203 (19) | 7 (10) | 12 (7)* | 21 (15) | 48 (37)* | 6 (15) |
| Medication (n, % assessments) | ||||||
| • non-cardiovascular | 201 (12) | 8 (9) | 15 (7) | 16 (9) | 26 (13) | 2 (3) |
| • antihypertensive/anticoagulants | 69 (4) | 22 (25)* | 60 (28)* | 47 (25)* | 4 (2) | 54 (75)* |
| Outcome characteristics | ||||||
| Birth weight, g | 3380±535 | 1280±536* | 2915±652* | 3069±744* | 2384±597* | 2941±914* |
| Birth weight, percentile | 55±27 | 27±26* | 43±31 | 45±32 | 4.4±2* | 45±32 |
| Gestational age at delivery (weeks) | 39.2±1.8 | 30.4±2.8* | 37.7±1.8* | 38.4±2.6* | 38.0±3.4* | 37.6±3.8* |
UP, uncomplicated pregnancy; EPE, early-onset preeclampsia; LPE, late-onset preeclampsia; GH, gestational hypertension; SGA, small for gestational age neonates; EH, essential hypertension. Data are presented as means ± SD or n (%).
*p<0.05 = significantly different from UP.